Management Change/Compensation (Form 8-K)

Item 5.02        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 12, 2025, the Compensation Committee of the Board of Directors of Traws Pharma, Inc. (the "Company") approved the grant of options to purchase shares of Company common stock (collectively, the "Options") to the Company's executive officers, as follows: 64,839 Options to Iain Dukes, the Company's Chief Executive Officer; 32,406 Options to Charles Parker, the Company's Chief Financial Officer; 32,406 Options to C. David Pauza, the Company's Chief Science Officer, Virology; 32,406 Options to Robert Redfield, the Company's Chief Medical Officer; and 22,435 Options to Nikolay Savchuk, the Company's Chief Operating Officer. The Options have an exercise price of $3.01 per share (the closing price of the Company's common stock on October 10, 2025), have a ten year term, and vest in full on the first anniversary of the grant date, subject to the respective recipient's continued service to the Company through the vesting date. The Options were granted under the Company's Amended and Restated 2021 Incentive Compensation Plan.